Dean Diagnostic Technology Group Co., Ltd. takes the third-party diagnostic service as the core business and is committed to providing integrated solutions for medical diagnosis. The company was founded in 2001 and listed in July 2011 (Stock Code: 300244). Its business covers medical diagnostic services, diagnostic technology research and development, diagnostic product production and marketing, CRO, judicial expertise, health management, cold chain logistics and other fields.

As a pioneer in the field of medical diagnosis in China, Dean diagnosis takes "let Chinese people share health equally" as its mission. At present, it has deployed 40 chain laboratories across the country, and is successively passing ISO15189 and cap international quality accreditation certification in the United States, providing services to more than 20000 medical institutions and more than 300 million people across the country, enabling the development of the great health industry.

The company adheres to the "one body and two wings" development mode with technology driving as the "body" and services and products as the left and right "wings", takes discipline building and technology platform as the core, realizes the research and transformation of products and testing projects, drives the continuous improvement of diagnostic product production and diagnostic service level, and creates an integrated solution in combination with data system, Improve the efficiency and value of medical diagnosis.

Based on the construction of four university departments of cancer, infection, chronic diseases and maternal and child genetics, focus on building two technical platforms of genomics, protein and metabolomics. At present, it has strong R & D advantages and product production capacity in the fields of gene sequencing, PCR, tandem mass spectrometry, nucleic acid mass spectrometry and pathological diagnosis. It has reached strategic cooperation with many universities and scientific research institutes in China, as well as many international well-known institutions such as Johns Hopkins University, Danaher group, FMI, Roche, Agena and NMS, At present, many technologies and products with independent intellectual property rights and patents have been launched. The company has been approved as the pilot unit for clinical application of high-throughput gene sequencing technology in the first batch of national cancer diagnosis and treatment projects, the first batch of national clinical application demonstration center for gene detection technology, and the national third-party high-performance medical diagnosis and treatment equipment application demonstration center.

Around the multiple stages of disease management, Dean diagnostics has built a trinity health diagnosis and treatment industry chain of "diagnosis technology R & D / production + diagnosis service + health management", which helps doctors carry out life-cycle health management for all kinds of people from the aspects of research, prevention, screening, diagnosis, efficacy monitoring, prognosis evaluation, chronic disease management and health management.

The company actively builds an international and professional talent team, with more than 40 overseas returned scholars, more than 500 with master's degree or above, and more than 3000 scientific and technical personnel, forming a professional technical talent echelon composed of discipline leaders, young and middle-aged backbone and young talents.

Relying on the comprehensive advantages of industrial ecological layout and driven by science and technology and digitization, Dean diagnosis will lay out disease management and health management schemes throughout the life cycle around a variety of diseases, become an integrated service provider of diagnosis and treatment with professional barriers, and better contribute to the construction of "healthy China 2030".